Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motolimod - Celgene

Drug Profile

Motolimod - Celgene

Alternative Names: VTX-2337

Latest Information Update: 18 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer VentiRx Pharmaceuticals
  • Class Amides; Antineoplastics; Benzazepines; Pyrrolidines; Small molecules
  • Mechanism of Action Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Breast cancer; Lymphoma
  • Discontinued B-cell lymphoma

Most Recent Events

  • 19 Oct 2018 Efficacy and safety data from a phase I/II study in ovarian cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Neoadjuvant therapy) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top